High 15-F2t-isoprostane levels in patients with a previous history of nonmelanoma skin cancer: The effects of supplementary antioxidant therapy

Página do item simplificado
dc.contributor.authorDe Jesus E Silva De Almendra Freitas B.
dc.contributor.authorLloret G.R.
dc.contributor.authorVisacri M.B.
dc.contributor.authorTuan B.T.
dc.contributor.authorAmaral L.S.
dc.contributor.authorBaldini D.
dc.contributor.authorDe Sousa V.M.
dc.contributor.authorDe Castro L.L.
dc.contributor.authorAguiar J.R.S.
dc.contributor.authorDe Carvalho Pincinato E.
dc.contributor.authorMazzola P.G.
dc.contributor.authorMoriel P.
dc.date.accessioned2024-03-13T00:58:22Z
dc.date.available2024-03-13T00:58:22Z
dc.date.issued2015
dc.description.abstractCopyright © 2015 Betânia de Jesus e Silva de Almendra Freitas et al.Background. Phase I of this study was aimed at comparing the profiles of oxidative stress biomarkers in patients with history of nonmelanoma skin cancer (NMSC), previously treated with surgery, to the healthy subjects. Phase II aimed to evaluate the effects of supplementary antioxidant therapy on the levels of biomarkers in the case group. Materials and Methods. In Phase I, oxidative stress biomarkers were measured in blood samples obtained from 24 healthy subjects and 60 patients with history of NMSC previously treated with surgery. In Phase II, the 60 patients with history of NMSC were randomized into two subgroups, one receiving placebo (n = 34) and the other (n = 26) receiving vitamin C, vitamin E, and zinc supplementation for 8 weeks, followed by reevaluation of biomarkers. Results. In Phase I, patients with history of NMSC showed increased plasma concentrations of all biomarkers, but only 15-F2t-isoprostane was significantly higher than in the healthy subjects. Risk of NMSC increased by 4% for each additional 1 pg/mL increase in 15-F2t-isoprostane. In Phase II, supplementation did not significantly reduce levels of oxidative stress biomarkers. Conclusion. Patients with history of NMSC had significantly high 15-F2t-isoprostane plasma levels; supplementation did not result in significant reduction of oxidative stress biomarkers. This trial was registered with ClinicalTrials.gov (ID NCT02248584).
dc.description.volume2015
dc.identifier.doi10.1155/2015/963569
dc.identifier.issn2314-6141
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/36264
dc.relation.ispartofBioMed Research International
dc.rightsAcesso Aberto
dc.titleHigh 15-F2t-isoprostane levels in patients with a previous history of nonmelanoma skin cancer: The effects of supplementary antioxidant therapy
dc.typeArtigo
local.scopus.citations8
local.scopus.eid2-s2.0-85016923593
local.scopus.subjectAdult
local.scopus.subjectAged
local.scopus.subjectAntioxidants
local.scopus.subjectAscorbic Acid
local.scopus.subjectBiomarkers, Tumor
local.scopus.subjectDietary Supplements
local.scopus.subjectFemale
local.scopus.subjectHumans
local.scopus.subjectIsoprostanes
local.scopus.subjectMale
local.scopus.subjectMiddle Aged
local.scopus.subjectOxidative Stress
local.scopus.subjectSkin Neoplasms
local.scopus.subjectVitamin E
local.scopus.subjectZinc
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016923593&origin=inward
Arquivos
Coleções
Artigos de periódico